Vapor of Volatile Oils from Litsea cubeba Seed Induces Apoptosis and Causes Cell Cycle Arrest in Lung Cancer Cells

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Seal, Soma ^a   Chatterjee, Priyajit ^a   Bhattacharya, Sushmita ^a   Pal, Durba ^a   Dasgupta, Suman ^a,b   Kundu, Rakesh ^a   Mukherjee, Sandip ^a   Bhattacharya, Shelley ^a   Bhuyan, Mantu ^b   Bhattacharyya, Pranab R ^b   Baishya, Gakul ^b   Barua, Nabin C ^b   Baruah, Pranab K ^b   Rao, Paruchuri G ^b   Bhattacharya, Samir ^a,b  

^a VISVA BHARATI UNIVERSITY   (India)

^b CSIR NORTH EAST INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIN D1; CYTOCHROME C; ESSENTIAL OIL; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SERINE; THREONINE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL CYCLE ARREST; CELL KILLING; CELL PROLIFERATION; CELL STRAIN A549; CELL SURVIVAL; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; INHALATIONAL DRUG ADMINISTRATION; LITSEA; LITSEA CUBEBA; LUNG NON SMALL CELL CANCER; MALE; NONHUMAN; PLANT SEED; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION; VAPOR;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; HUMANS; LITSEA; LUNG NEOPLASMS; OILS, VOLATILE; PHOSPHORYLATION; PLANT EXTRACTS; PLANT OILS; PROTO-ONCOGENE PROTEINS C-AKT; SEEDS; SIGNAL TRANSDUCTION;

EID: 84867600488     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047014     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, (2011) Global cancer statistics. CA Cancer J Clin 66: 69-90.
2. Nacht M, Dracheva T, Gao Y, Fujii T, Chen Y, et al. (2001) Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci 98: 15203-15208.
3. Tyagi P, Belani CP, Jain VK, (2005) Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small cell lung cancer: results from the SPIRIT I and II trials. Clin Lung Cancer 7: 17-19.
4. Schuurbiers Olga CJ, Kaanders JHAM, van der Heijden HFM, Dekhuijzen RPN, Oyen WJG, et al. (2009) The PI3-K/AKT-Pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4: 761-767.
5. Brognard J, Clark AS, Ni Y, Dennis PA, (2001) Akt/Protein Kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997.
6. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, et al. (1998) Protein Kinase B kinases that mediate Phosphatidylinositol 3,4,5-Trisphosphate dependent activation of Protein Kinase B. Science 279: 710-714.
7. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 307: 1098-1101.
8. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, et al. (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059.
9. Franke TF, Cantley LC, (1997) A Bad kinase makes good. Nature 390: 116-117.
10. Sinha S, Pal BC, Jagadeesh S, Banerjee PP, Bandyopadhaya A, et al. (2006) Mahanine inhibits growth and induces apoptosis in prostate cancer cells through the deactivation of Akt and activation of caspases. Prostate 66: 1257-1265.
11. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB, (2002) Inhibition of Phosphatidylinositol 3′-Kinase increases efficacy of Paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092.
12. Elrod HA, Lin YD, Yue P, Wang X, Lonial S, et al. (2007) The alkyl phospholipids perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 6: 2028-2038.
13. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, et al. (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973-982.
14. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, et al. (1995) Bad, a heterodimeric partner for Bcl-xl, and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291.
15. Ottilie S, Diaz JL, Horne W, Chang J, Wang Y, et al. (1997) Dimerization properties of human BAD identification of a BH-3 domain and analysis of its binding to mutant bcl-2 and bcl-xl proteins. J Biol Chem 272: 30866-30872.
16. Datta SR, Dudek H, Tao X, Masters S, Fu H, et al. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
17. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ, (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 87: 619-628.
18. Kropp PJ, Breton GW, Craig SL, Crawford SD, Durland WF Jr, et al. (1995) Surface-mediated reactions. 6. Effects of silica gel and alumina on acid-catalyzed reactions. Org Chem 60: 4146-4152.
19. Lowry OH, Rosebrough NJ, Farr AE, Randall RJ, (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193: 265-275.
20. Liu G, Xia T, Chen X, (2003) The activation domains, the proline-rich domain, and the c-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J Biol Chem 278: 17557-17565.
21. Phan SH, Varani J, Smith D, (1985) Rat lung fibroblast collagen metabolism in bleomycin-induced pulmonary fibrosis. J Clin Invest 76: 241-247.
22. Salvesen GS, Riedl SJ, (2007) Caspase mechanisms. Adv Exp Med Biol 615: 3-23.
23. Mishina T, Dosaka-Akita H, Kinoshita I, Hommura F, Morikawa T, et al. (1999) Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome. Brit J Cancer 80: 1289-1295.
24. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
25. El-Deiry, Tokino WS, Velculescu T, Levy VE, Parsons DB, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
26. Han JW, Ahn SH, Kim YK, Bae GU, Yoon JW, et al. (2001) Activation of p21WAF1/Cip1 transcription through Sp1 sites by histone deacetylase inhibitor apicidin. Involvement of protein kinase C. J Biol Chem 276: 42084-42090.
27. Srivastava RC, (2009) Adi Community (2009) Traditional knowledge of Adi tribe of Arunachal Pradesh on plants. Ind J Trad Know 8: 146-153.
28. Namsa ND, Mandal M, Tangjang S, Mandal SC, (2011) Ethnobotany of the Monpa ethnic group at Arunachal Pradesh, India. J Ethnobio Ethnomed 31: 1-14.
29. Nadkar A, Pungaliya C, Drake K, Zajac E, Singhal SS, et al. (2006) Therapeutic resistance in lung cancer. Expert Opin Drug Met 2: 753-777.
30. David O, Jett J, LeBeau H, Dy G, Hughes J, et al. (2004) Phospho-Akt over expression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10: 6865-6871.
31. Tang JM, He QY, Guo RX, Chang XJ, (2006) Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191.
32. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, et al. (2004) Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 170: 1088-1094.
33. Vincent EE, Elder DJ, Thomas EC, Phillips L, Morgan C, et al. (2011) Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer 104: 1755-1761.
34. Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, et al. (2006) Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24: 306-314.
35. Soldani C, Scovassi AI, (2002) Poly (ADP-ribose) polymerase-1 cleavage during apoptosis: An update. Apoptosis 7: 321-328.
36. Mayo LD, Donner DB, (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci 98: 11598-11603.
37. Levine AJ, (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
38. Spira A, Ettinger DS, (2004) Multidisciplinary management of lung cancer. N Engl J Med 350: 379-392.
39. Sandler A, Gray R, Perry MC, Brahmer J, Schille JH, et al. (2006) Paclitaxel-Carboplatin alone or with Bevacizumab for non-small cell lung cancer. N Engl J Med 355: 2542-2550.
40. Scripture CD, Figg WD, Sparreboom A, (2006) Peripheral neuropathy induced by Paclitaxel: Recent insights and future perspectives. Curr Neuropharmacol 4: 165-172.
41. Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker SD, (1999) Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res 5: 767-74.
42. Nimako K, Popat S, (2012) Management of lung cancer. Medicine 40: 202-207.
43. Maira SM, Furet P, Stauffer F, (2009) Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. Future Med Chem 1: 137-55.